PMID- 36599111
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240419
IS  - 2372-952X (Print)
IS  - 2372-952X (Electronic)
IS  - 2372-952X (Linking)
VI  - 10
IP  - 1
DP  - 2023 Jan 25
TI  - Associations Between Muscle Weakness and Clinical Outcomes in Current and Former 
      Smokers.
PG  - 112-121
LID - 10.15326/jcopdf.2022.0365 [doi]
AB  - INTRODUCTION: Smokers with chronic obstructive pulmonary disease (COPD) are at 
      increased risk of muscle weakness. There are limited data describing weakness in 
      smokers with normal spirometry and preserved ratio-impaired spirometry (PRISm), 2 
      subgroups at risk of respiratory symptom burden and activity limitations. In this 
      study, we evaluated the associations of 2 weakness measures, sit-to-stand (STS) 
      and handgrip strength (HGS), with clinical outcomes in smokers with COPD, normal 
      spirometry, and PRISm. METHODS: We evaluated 1972 current and former smokers from 
      the COPD Genetic Epidemiology (COPDGene((R))) cohort with STS and HGS measurements 
      at their 10-year study visit. Multivariable regression modeling was used to 
      assess associations between weakness measures and the 6-minute walk distance 
      (6MWD) test, the St George's Respiratory Questionnaire (SGRQ), the Short-Form-36 
      (SF-36), severe exacerbations, and prospective mortality, reported as 
      standardized coefficients (beta), odds ratios (ORs), or hazard ratios (HRs). 
      RESULTS: Compared with HGS, STS was more strongly associated with the 6MWD 
      (beta=0.45, p<0.001 versus. beta=0.25, p<0.001), SGRQ (beta=-0.24, p<0.001 versus beta=-0.18, 
      p<0.001), SF-36 Physical Functioning (beta=0.36, p<0.001 versus beta=0.25, p<0.001), 
      severe exacerbations (OR 0.95, p=0.04 versus OR 0.97, p=0.01), and prospective 
      mortality (HR 0.83, p=0.001 versus HR 0.94, p=0.03). Correlations remained after 
      stratification by spirometric subgroups. Compared with males, females had larger 
      magnitude effect sizes between STS and clinical outcomes. CONCLUSIONS: STS and 
      HGS are easy to perform weakness measures that provide important information 
      about functional performance, health-related quality of life, severe 
      exacerbations, and survival in smokers, regardless of spirometric subgroup. This 
      iterates the importance of screening current and former smokers for weakness in 
      the outpatient setting.
CI  - JCOPDF (c) 2023.
FAU - Zou, Richard H
AU  - Zou RH
AD  - Division of Pulmonary, Allergy, and Critical Care Medicine, Department of 
      Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 
      United States.
FAU - Nouraie, S Mehdi
AU  - Nouraie SM
AD  - Division of Pulmonary, Allergy, and Critical Care Medicine, Department of 
      Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 
      United States.
FAU - Rossiter, Harry B
AU  - Rossiter HB
AD  - The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, 
      Torrance, California, United States.
FAU - McDonald, Merry-Lynn
AU  - McDonald ML
AD  - Division of Pulmonary, Allergy, and Critical Care Medicine, Department of 
      Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United 
      States.
FAU - DeMeo, Dawn L
AU  - DeMeo DL
AD  - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham 
      and Women's Hospital, Boston, Massachusetts, United States.
FAU - Mason, Stefanie
AU  - Mason S
AD  - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham 
      and Women's Hospital, Boston, Massachusetts, United States.
FAU - Washko, George R
AU  - Washko GR
AD  - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham 
      and Women's Hospital, Boston, Massachusetts, United States.
FAU - Saha, Punam K
AU  - Saha PK
AD  - Department of Radiology, University of Iowa, Iowa City, Iowa, United States.
FAU - Make, Barry J
AU  - Make BJ
AD  - Department of Medicine, National Jewish Health, Denver, Colorado, United States.
FAU - Casaburi, Richard
AU  - Casaburi R
AD  - The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, 
      Torrance, California, United States.
FAU - Regan, Elizabeth A
AU  - Regan EA
AD  - Department of Medicine, National Jewish Health, Denver, Colorado, United States.
FAU - Bon, Jessica
AU  - Bon J
AD  - Division of Pulmonary, Allergy, and Critical Care Medicine, Department of 
      Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 
      United States.
AD  - Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United 
      States.
CN  - COPDGene Investigators
LA  - eng
GR  - F32 HL164309/HL/NHLBI NIH HHS/United States
GR  - R01 HL153460/HL/NHLBI NIH HHS/United States
GR  - U01 HL089897/HL/NHLBI NIH HHS/United States
GR  - U01 HL089856/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Chronic Obstr Pulm Dis
JT  - Chronic obstructive pulmonary diseases (Miami, Fla.)
JID - 101635411
PMC - PMC9995230
OTO - NOTNLM
OT  - COPD outcomes
OT  - COPDGene
OT  - chronic obstructive pulmonary disease
OT  - cigarette smoking
OT  - musculoskeletal comorbidities
COIS- HBR reports grants and contracts from the NIH and Tobacco-Related Disease 
      Research Program, consulting fees from Omniox, and is involved in contracted 
      clinical research with Boehringer Ingelheim, GlaxoSmithKline, Novartis, 
      AstraZeneca, Astellas, United Therapeutics, Genentech, and Regeneron; he is a 
      visiting Professor at the University of Leeds, United Kingdom. DLD reports grants 
      and contracts from the NIH and Bayer. GRW reports grants and contracts from the 
      NIH, Department of Defense, and Boehringer Ingelheim, consulting fees from 
      Pulmonx, Vertex, and Janssen Pharmaceuticals, participation on a data safety 
      monitoring board for Pulmonx and is a co-founder and equity shareholder in 
      Quantitative Imaging Solutions, a company that provides consulting and software 
      development services for image and data analytics; GRW's wife works for Biogen. 
      BJM reports grants and contracts from NHLBI, American Lung Association, 
      Department of Defense, AstraZeneca, and Pearl, consulting fees from AstraZeneca 
      and Third Pole, royalties from Wolters Kluwer Health (UpToDate), and 
      participation on data safety monitoring boards for Spiration, Mylan, Quintiles, 
      Mount Sinai, University of Wisconsin, and Baystate Medical Center; he serves on 
      medical advisory boards for GlaxoSmithKline, Boehringer Ingelheim, and 
      AstraZeneca. RC reports grants and contracts from Regeneron and speaker bureau 
      participation with GlaxoSmithKline and Boehringer Ingelheim; he serves on the 
      medical advisory board and has stock ownership with Inogen. RHZ, SMN, MLM, SM, 
      PKS, EAR, and JB have no conflicts to disclose.
EDAT- 2023/01/05 06:00
MHDA- 2023/01/05 06:01
PMCR- 2023/01/05
CRDT- 2023/01/04 16:02
PHST- 2023/01/05 06:00 [pubmed]
PHST- 2023/01/05 06:01 [medline]
PHST- 2023/01/04 16:02 [entrez]
PHST- 2023/01/05 00:00 [pmc-release]
AID - 10.15326/jcopdf.2022.0365 [doi]
PST - ppublish
SO  - Chronic Obstr Pulm Dis. 2023 Jan 25;10(1):112-121. doi: 
      10.15326/jcopdf.2022.0365.